

Supplementary data for

CD44v6-Mediated Regulation of Gastric Cancer Stem Cells: A Potential Therapeutic Target

**Hao Chen ^{1#}, Ruoyu Ling ^{1#}, Jiayu Lai ², Zhiqi Liu ², Zhe Wang ^{3*}, Hua Yang ^{4*},
Yi Kong ^{5*}**

1. Department of General Surgery & Guangdong Provincial Key Laboratory of Precision Medicine for Gastrointestinal Tumor, Nanfang Hospital, Southern Medical University, Guangzhou, China

2. The First School of Clinical Medicine, Southern Medical University, Guangzhou, China.

3. Department of Oncology, The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, Guangdong Province, 510080, China

4. Department of Basic Medicine, School of Medicine, Foshan University, Foshan, Guangdong Province, 528000, China

5. Faculty of Pharmaceutical Sciences, Shenzhen University of Advanced Technology (SUAT), Shenzhen, Guangdong Province, 518107, China.

[#] These authors contributed equally to this work.

^{*} Correspondence.

E-mail addresses: kongyi@suat-sz.edu.cn (Y, Kong), huayang@fosu.edu.cn (H, Yang), wangzhe@gdpu.edu.cn (Z, Wang)

Keywords: gastric cancer, CD44v6, cancer stem cell, tumor progression, chemoresistance

Supplementary figure

Fig. S1




Fig.S1. Effect of CD44v6 knockdown on anchorage-independent growth of gastric cancer cells. (a) Soft agar colony formation assays demonstrate the anchorage-independent growth capacity of control and CD44v6 knockdown cells. Representative images show a reduced number and size of colonies in the CD44v6 knockdown group. Scale bars: 100 μ m. (b) Quantitative analysis of the number of colonies formed shows a significant reduction in the CD44v6 knockdown group compared to the control group. (c) Microscopic examination highlights morphological differences between colonies formed by control and CD44v6 knockdown cells, with visibly smaller and less developed colonies in the knockdown group. Scale bars: 50 μ m. (d) Quantitative analysis of colony diameter reveals significantly smaller colonies in the CD44v6 knockdown group compared to the control group. Mean \pm SD of three independent assays is shown, significant differences to control cells: * $p < 0.05$, ** $p < 0.01$, and *** $p < 0.001$.

Supplementary Tables

Table S1. Primer sequence used in this study.

| Gene | sequence |
|---------------|--------------------------------|
| CD44V6 | |
| F | 5' GATGTCACAGGTGGAAGAAG 3' |
| R | 5' GGCCTGCTTTCCTTCGTGT 3' |
| Nanog | |
| F | 5' AGAGAAGAGTGTCGCAAAAAAGGA 3' |
| R | 5' TGAGGTTCAGGATGTTGGAGAGTT 3' |
| Oct4 | |
| F | 5' CACAACGAGAGGATTTTGAGGCTG 3' |
| R | 5' GCAGTGAAGTGAGGGCTCCCATAG 3' |
| SOX2 | |
| F | 5' CACCCCTGGCATGGCTCTTG 3' |
| R | 5' TGGAGTGGGAGGAAGAGGTAAC 3' |

Table S2. Information on antibodies used in this study.

| Antibody | WB | Specificity | Company |
|------------------------|---------|-------------------|---------|
| CD44v6(ab205719) | 1:2000 | Mouse polyclonal | Abcam |
| CD44(ab243894) | 1:1000 | Rabbit monoclonal | Abcam |
| CD24(ab290730) | 1:1000 | Rabbit monoclonal | Abcam |
| CD133 (ab19898) | 1:1000 | Rabbit polyclonal | Abcam |
| EpCAM(ab223582) | 1:1000 | Rabbit monoclonal | Abcam |
| β -actin (A5441) | 1:10000 | Mouse monoclonal | Sigma |